Erste Asset Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $379K | Hold |
26,900
| – | – | ﹤0.01% | 673 |
|
|
2025
Q1 | $398K | Hold |
26,900
| – | – | 0.01% | 444 |
|
|
2024
Q4 | $554K | Hold |
26,900
| – | – | 0.01% | 432 |
|
|
2024
Q3 | $792K | Hold |
26,900
| – | – | 0.01% | 400 |
|
|
2024
Q2 | $618K | Hold |
26,900
| – | – | 0.01% | 407 |
|
|
2024
Q1 | $559K | Hold |
26,900
| – | – | 0.01% | 411 |
|
|
2023
Q4 | $590K | Sell |
26,900
-307,769
| -92% | -$6.76M | 0.01% | 414 |
|
|
2023
Q3 | $684K | Buy |
334,669
+307,769
| +1,144% | +$629K | 0.01% | 378 |
|
|
2023
Q2 | $790K | Hold |
26,900
| – | – | 0.01% | 383 |
|
|
2023
Q1 | $589K | Hold |
26,900
| – | – | 0.01% | 413 |
|
|
2022
Q4 | $757K | Hold |
26,900
| – | – | 0.02% | 387 |
|
|
2022
Q3 | $788K | Hold |
26,900
| – | – | 0.02% | 375 |
|
|
2022
Q2 | $780K | Hold |
26,900
| – | – | 0.02% | 385 |
|
|
2022
Q1 | $872K | Sell |
26,900
-3,700
| -12% | -$120K | 0.02% | 372 |
|
|
2021
Q4 | $1.35M | Hold |
30,600
| – | – | 0.02% | 328 |
|
|
2021
Q3 | $1.51M | Hold |
30,600
| – | – | 0.03% | 301 |
|
|
2021
Q2 | $2.35M | Hold |
30,600
| – | – | 0.05% | 271 |
|
|
2021
Q1 | $1.66M | Hold |
30,600
| – | – | 0.04% | 295 |
|
|
2020
Q4 | $2.57M | Sell |
30,600
-111,600
| -78% | -$9.37M | 0.07% | 240 |
|
|
2020
Q3 | $5.11M | Hold |
142,200
| – | – | 0.17% | 142 |
|
|
2020
Q2 | $3.42M | Hold |
142,200
| – | – | 0.14% | 169 |
|
|
2020
Q1 | $2.58M | Hold |
142,200
| – | – | 0.15% | 163 |
|
|
2019
Q4 | $2.5M | Hold |
142,200
| – | – | 0.11% | 183 |
|
|
2019
Q3 | $2.2M | Hold |
142,200
| – | – | 0.12% | 172 |
|
|
2019
Q2 | $2.94M | Buy |
142,200
+100,000
| +237% | +$2.07M | 0.16% | 139 |
|
|
2019
Q1 | $944K | Buy |
42,200
+29,000
| +220% | +$649K | 0.05% | 251 |
|
|
2018
Q4 | $257K | Buy |
+13,200
| New | +$257K | 0.02% | 350 |
|